Background: Venous thromboembolism (VTE) is a serious threat for all cancer patients. This study was aimed to assess the VTE treatment of cancer patients in the ambulatory care setting. Patients and Methods: This is a prospective non-interventional study, which includes ambulatory cancer patients from office-based oncologists. A standardized case report form was used to obtain data on patient characteristics, treatment regimens, duration of treatment, and side effects. Results: Specialists from 34 centers included data from 76 patients. The median patient age was 62 years (range 33-81 years). The 4 most common cancer types were breast cancer (32%), colorectal cancer (18%), lymphoma and lung cancer (each 8%). 18% of the acute VTE cases were treated as inpatients, 80% as outpatients, and 99% with low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux. After the acute phase, secondary prophylaxis with LMWH/UFH/fondaparinux was planned in 61% of the patients, with oral anticoagulation in 39%. During acute-phase treatment and secondary prophylaxis, no patient had recurrent VTE. 4 patients (5%) experienced minor bleedings. Conclusions: This study shows that many ambulatory cancer patients with VTE have early tumors, no metastases, and an excellent performance score. Most patients receive LMWHs for secondary prophylaxis, as recommended by the national and international guidelines. Still, a relevant percentage is switched to oral anticoagulants.

1.
Paneesha S, McManus A, Arya R, Scriven N, Farren T, Nokes T, Bacon S, Nieland A, Cooper D, Smith H, O'Shaughnessy D, Rose P; VERITY Investigators: Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost 2010;103:338-343.
[PubMed]
2.
Sallah S, Wan JY, Nguyen NP: Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.
[PubMed]
3.
Gil-Bernabé A, Lucotti S, Muschel RJ: Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol 2013;162:433-441.
[PubMed]
4.
Lin RJ, Afshar-Kharghan V, Schafer AI: Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood 2014;124:184-187.
[PubMed]
5.
Sørensen HT, Mellemkjær L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
[PubMed]
6.
Chew HK, Wun T, Harvey D, Zhou H, White RH: The incidence of venous thromboembolism and its effect on survival among patients with common cancer. Arch Intern Med 2006;166:458-464.
[PubMed]
7.
Kuderer NM, Ortel TL, Francsi CW: Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009;27:4902-4911.
[PubMed]
8.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
[PubMed]
9.
Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.
[PubMed]
10.
Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; ONCENOX Investigators: Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-396.
[PubMed]
11.
Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators: Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-1072.
[PubMed]
12.
Akl EA, Labedi N, Barba M, Terrenato I, Sperati F, Muti P, Schünemann H: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011;(6):CD006650.
[PubMed]
13.
Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, Khorana AA; CATCH Investigators: CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013;13:284.
[PubMed]
14.
Lee AY, Kamphuisen PW, MD, Meyer G, Bauersachs R, Janas M, Jarner MF, Khorana AA; CATCH Investigators: A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study. Blood 2014;124:abstr LBA-2.
15.
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR: International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013;11:56-70.
[PubMed]
16.
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A; American Society of Clinical Oncology Clinical Practice: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2189-2204.
[PubMed]
17.
NCCN Clinical Practice Guidelines in Oncology: Cancer-associated venous thromboembolic disease. Version 1/2014, www.nccn.org [accessed December 12, 2014].
18.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634.
[PubMed]
19.
Caprini JA, Tapson VF, Hyers TM, Waldo AL, Wittkowsky AK, Friedman R, Colgan KJ, Shillington AC; NABOR Steering Committee: Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg 2005;42:726-733.
[PubMed]
20.
Schellong SM, Gerlach H, Hach-Wunderle V, Rabe E, Riess H, Carnarius H, Eberle S, Bauersachs R: Diagnosis of deep-vein thrombosis: adherence to guidelines and outcomes in real-world health care. Thromb Haemost 2009;102:1234-1240.
[PubMed]
21.
Wittkowsky AK: Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 2006;4:2090-2091.
[PubMed]
22.
Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, Rossi R, Verso M; MASTER Investigators: Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 2008;93:273-278.
[PubMed]
23.
Wright JD, Lewin SN, Shah M, Burke WM, Lee SM, Sun X, Herzog TJ: Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery. Ann Surg 2011;253:1140-1146.
[PubMed]
24.
Abdel-Razeq H, Albadainah F, Hijjawi S, Mansour A, Treish I: Venous thromboembolism (VTE) in hospitalized cancer patients: prophylaxis failure or failure to prophylax! J Thromb Thrombolysis 2011;31:107-112.
[PubMed]
25.
Spirk D, Ugi J, Korte W, Husmann M, Hayoz D, Baldi T, Frauchiger B, Banyai M, Aujesky D, Baumgartner I, Kucher N: Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II. Thromb Haemost 2011;105:962-967.
[PubMed]
26.
Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, Schrag D: Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist 2012;17:419-427.
[PubMed]
27.
Marchena PJ, Nieto JA, Guil M, García-Bragado F, Rabuñal R, Boccalon H, Trujillo-Santos J, Monreal M; RIETE Investigators: Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism. Thromb Haemost 2012;107:37-43.
[PubMed]
28.
Belhadj Chaidi R, Thollot C, Ferru A, Roblot P, Landron C: Adherence to guidelines for the treatment of venous thromboembolism in cancer patients: a retrospective analysis of 145 cases [in French]. J Mal Vasc 2013;38:185-192.
[PubMed]
29.
Kleinjan A, Hutten B, Di Nisio M, Kamphuisen PW, Büller HR: Anticoagulant treatment of cancer patients with pulmonary embolism in the real world. J Thromb Haemost 2013;11(suppl 2):987, abstr PB 4.61-3.
30.
Rahme E, Feugère G, Sirois C, Weicker S, Ramos E: Anticoagulant use in patients with cancer associated venous thromboembolism: a retrospective cohort study. Thromb Res 2013;131:210-217.
[PubMed]
31.
Sevestre MA, Belizna C, Durant C, Bosson JL, Vedrine L, Cajfinger F, Debourdeau P, Farge D; Carmen Investigators for the Groupe Francophone Thrombose et Cancer (GFTC): Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc 2014;39:161-168.
[PubMed]
32.
den Exter PL, Hooijer J, Dekkers OM, Huisman MV: Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011;29:2405-2409.
[PubMed]
33.
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
[PubMed]
You do not currently have access to this content.